Article Text

Download PDFPDF

338 Effects of pembrolizumab on the tumor microenvironment (TME) after one presurgery treatment cycle in patients with triple-negative breast cancer (TNBC): phase 1b KEYNOTE-173 study
  1. Peter Schmid1,
  2. Yeon Hee Park2,
  3. Eva Muñoz-Couselo3,
  4. Sung-Bae Kim4,
  5. Joohyuk Sohn5,
  6. Seock-Ah Im6,
  7. Esther Holgado7,
  8. Theodoros Foukakis8,
  9. Sherko Kümmel9,
  10. Rebecca Dent10,
  11. Yuan Sun11,
  12. Lingkang Huang11,
  13. Jennifer Yearley11,
  14. Petar Jelinic11,
  15. Vassiliki Karantza11 and
  16. Javier Cortés3
  1. 1Centre for Experimental Cancer Medicine, London, UK
  2. 2Samsung Medical Center, Seoul, Korea, Republic of
  3. 3Vall d´Hebron Institute of Oncology (VHIO), Barcelona, Spain
  4. 4Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea, Republic of
  5. 5Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Korea, Republic of
  6. 6Seoul National University Hospital, Cancer Research Institute, Seoul National University College of Medicine, Seoul, Korea, Republic of
  7. 7Ramón y Cajal University, Madrid, Spain
  8. 8Karolinska Institutet and Breast Cancer Center, Theme Cancer, Karolinska University Hospital, Solna, Sweden
  9. 9Kliniken Essen-Mitte, Essen, Germany
  10. 10International Breast Cancer Center Quironsalud Group, Singapore, Singapore
  11. 11Merck and Co., Inc., Kenilworth, NJ, USA


Background In the phase 3 KEYNOTE-522 trial, neoadjuvant pembrolizumab+chemotherapy followed by adjuvant pembrolizumab monotherapy resulted in a statistically significant improvement in pathologic complete response (pCR) and event-free survival, compared with neoadjuvant chemotherapy alone, in patients with early-stage TNBC. In the phase 1b KEYNOTE-173 (NCT02622074) trial—another neoadjuvant pembrolizumab+chemotherapy trial—we evaluated TNBC biopsy samples at baseline and collected after one cycle of neoadjuvant pembrolizumab, before the initiation of chemotherapy, to explore the features within the TME at both timepoints that might be potentially predictive of clinical response and the effects of a single cycle of pembrolizumab on cell populations within the TME.

Methods Twenty paired samples (baseline and obtained following one cycle of pembrolizumab before the initiation of chemotherapy) were included. Multiplex immunohistochemistry analyzed deconvoluted cell fractions by spatial localization (tumor compartment, stromal compartment, or total tumor) using three 6-plex panels: T cell (CD3/CD8/FoxP3/Ki67/granzyme B/PD-1), myeloid cell (CD68/CD163/MHCII/arginase/CD33/CD11c), and natural killer cell (CD16/CD56/CD11b/CD20/CD3/CD45). Area under the receiver operating characteristic (AUROC) was used to assess associations between immune subsets and pCR. Analyses were descriptive, with top-ranked findings reported, and were deemed hypothesis generating; no claims of statistical significance are made.

Results At baseline, 6 of 75 evaluated immune subsets (counting different compartments) showed 95% CIs of AUROC not crossing 0.5 with pCR. These include some myeloid cell populations within the tumor compartment (AUROC, 95% CI), specifically CD11c+ (macrophage and dendritic cell [DC]: 0.85, 0.63–1.00), CD11c+/MHCII+/CD163/CD68 (DC: 0.76, 0.53–0.99), CD11c+/MHCII/CD163/CD68 (nonactivated/immature DC: 0.8, 0.54-1.00), and CD11c+/CD163+ (M2 macrophage: 0.77, 0.55–0.99). Other associations with pCR included baseline CD11c+/MHCII/CD163/CD68 (nonactivated/immature DC) within the total tumor (AUROC, 0.76; 95% CI, 0.51–1.00) and the baseline ratio of CD11c/CD3 within the tumor compartment (AUROC, 0.75; 95% CI, 0.52–0.98). Although T-cell associations were relatively weak, specific CD8 subsets, especially CD8+/granzyme B+/Ki67+, showed a trend toward association. Negative correlations between change from baseline and baseline values were observed; therefore, baseline detrending was applied to change from baseline values. One immune subset showed a negative association trend between change from baseline and pCR after baseline detrending: CD163+/MHCII+ (DC3) within the stroma (AUROC, 0.2; 95% CI, 0.0–0.42).

Conclusions Although the sample size in this exploratory analysis was small (n=20), myeloid cell populations within the tumor compartment at baseline show a promising association trend, as evaluated by AUROC, with pCR after neoadjuvant pembrolizumab+chemotherapy in early-stage TNBC. Changes in immune subsets following one cycle of pembrolizumab were not strongly associated with pCR.

ClinicalTrials gov, NCT02622074

Ethics Approval The study protocol and all amendments were approved by the relevant institutional review board or ethics committee at each study site.

Consent All patients provided written informed consent to participate in the clinical trial.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.